Related Experiment Video
Updated: Jul 30, 2026
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
[Improving the management of celiac disease: an urgent challenge]
1Instituto de Nutrición y Tecnología de los Alimentos, Universidad de Chile, Casilla, Santiago, Chile. maraya@inta.cl
Insights
Celiac disease affects 0.5-1% of the population, necessitating widespread antibody testing. Chile must assess its population for celiac disease and improve food labeling regulations.
Area of Science:
- Immunology
- Gastroenterology
- Public Health
Context:
- Celiac disease prevalence is higher than previously estimated globally (0.5-1%).
- Atypical presentations require active screening in high-risk groups.
- Chile lacks awareness of recent advancements in celiac disease diagnosis and management.
Purpose:
- To highlight the need for assessing the Chilean population for celiac disease using EMA/TTG antibody tests.
- To advocate for improved legal regulations regarding gluten content information in processed foods.
- To review key aspects for enhancing celiac patient management in Chile.
Summary:
- Antibody measurements (EMA/TTG) reveal celiac disease affects 0.5-1% of the population.
- Chile's current national data (1:1836 live births) is comparable to European rates.
- Urgent actions include population screening and enhanced food labeling laws.
Impact:
- Implementation of EMA/TTG testing can improve celiac disease diagnosis rates in Chile.
- Enhanced food labeling will empower consumers and aid in disease management.
- Collaboration with health authorities is crucial for effective policy implementation and patient care.
Abstract:
Anti endomysial and anti transglutaminase (EMA/TTG) antibodies measurements in large population groups, show that celiac disease is significantly more common than previously thought and 0.5-1% of the population suffer this condition. The recognition of atypical clinical presentations by active screening of high risk groups is a successful global initiative. In Chile there is little awareness of the enormous changes occurred in this field. Available national information on typical presentation of the disease shows that it is found in 1:1836 live births, figure that is comparable to European societies. Two urgent tasks are required in our country. First, to asses the Chilean population using EMA and/or TTG. Second, to improve the legal aspects that regulate consumer information about gluten content in processed foods. We here review the most relevant aspects to be considered to improve the management of celiac patients and the tasks that require the participation of health authorities for their implementation.
Related Concept Videos
01:24Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...